We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Creo Medical Group Plc | LSE:CREO | London | Ordinary Share | GB00BZ1BLL44 | ORD GBP0.001 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.50 | 2.70% | 19.00 | 18.50 | 19.50 | 19.00 | 18.50 | 18.50 | 552,305 | 13:47:54 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Surgical,med Instr,apparatus | 30.8M | -21.7M | -0.0600 | -3.17 | 66.87M |
Date | Subject | Author | Discuss |
---|---|---|---|
15/1/2025 07:03 | Creo Medical Group plc("Creo" the "Company" or the "Group") First robotic-guided lung ablation cases commenceas part of Intuitive collaboration agreement Robotic-guided microwave ablation of cancerous lung tissue now being undertaken at two UK sites Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that the first robotic-guided microwave ablation of cancerous lung tissue cases have commenced at a leading UK hospital (the "Hospital"). As announced in July 2024, the Company amended its multi-year collaboration with Intuitive and this latest robotic-guided microwave ablation procedure for lung cancer is the first clinical case using Intuitive's Ion Endoluminal System and Creo's MicroBlate Flex ablation device to take place under the amended terms of the agreement at the Hospital. The Hospital is now the second site to have performed microwave ablation procedures for lung cancer. The first UK site to perform such procedures was the Royal Brompton Hospital as part of an ongoing clinical study1 conducted by Professor Shah. The Pioneer Programme will continue to roll-out throughout 2025 to support the collection of clinical evidence ahead of the sites entering a commercial phase, and the Company expects the number of procedures performed to grow in the current year. Craig Gulliford, Chief Executive Officer of Creo, said: "We are delighted that this first clinical site under the Pioneer Programme, representing a second UK clinical site, has started clinical practice and successfully completed their first robotic-guided lung cancer ablation procedure using Creo's MicroBlate Flex alongside Intuitive's Ion Endoluminal System. With both the clinical study at the Royal Brompton and this site as part of the clinical Pioneer Programme, we now have two UK hospitals undertaking these procedures. These sites, under the amended collaboration agreement with Intuitive, will provide us with the clinical evidence needed to support the wider commercialisation of the MicroBlate Flex device. We look forward to updating shareholders on our progress." | bloomberg2 | |
14/1/2025 20:29 | https://youtu.be/nqX | bloomberg2 | |
13/1/2025 19:26 | https://youtu.be/ZiI | bloomberg2 | |
13/1/2025 10:03 | I am super confident with the people in charge here. Their track record is outstanding. This will come good. | protrader3 | |
13/1/2025 09:10 | Apologies Pro trader, yes I sound like some nasty old woman. Actually love the tech and provides a good investment and trading opportunity if all goes to plan. I just wish management wouldn't treat it like they were running a hedge fund on the remuneration. | peterrr3 | |
12/1/2025 18:02 | https://youtu.be/7mv | bloomberg2 | |
12/1/2025 16:09 | What's not to like Bloomberg? Maybe the fact they have been trying to grow the market/sales of speedboat for years now and failing at every metric, whilst having management paying themselves obscene amounts of money. I can't reconcile that. | peterrr3 | |
11/1/2025 18:47 | https://youtu.be/oaT | bloomberg2 | |
11/1/2025 09:30 | What's not to like | bloomberg2 | |
11/1/2025 09:30 | The speed boat! A One and DONE Procedure ...... | bloomberg2 | |
11/1/2025 09:29 | https://www.hopkinsm | bloomberg2 | |
11/1/2025 09:27 | https://x.com/creoen | bloomberg2 | |
08/1/2025 08:56 | Creo back 2019/2020 had been trading at around £2.37 and over a 4 Year period has seen a downward Diluted stock. Like most Large Private investors I’ve had to buy into even More Shares to break Even. | yasirallrico1 | |
08/1/2025 01:15 | I’ve had No choice but to counter balance my loses with a further £50,000 at some point. I should at least break even. | yasirallrico1 | |
07/1/2025 22:27 | I bought a few the other day without much research to be honest. It must have had a big market cap at 2.37p or has it been diluted since then ? | amt | |
07/1/2025 20:56 | Blimey Yas that was a serious investment!! Hope we can make a serious recovery this year and get you someways to make a full recovery in your fortunes | bloomberg2 | |
06/1/2025 22:08 | I’m currently down £58,000 buying a large Potion at 2.37 Per share. It’s been one of the worst Stocks I’ve traded. | yasirallrico1 | |
06/1/2025 14:07 | Well we are up 1p today so grateful for small mercies I guess. | bmcollins | |
06/1/2025 13:54 | https://x.com/creome | bloomberg2 | |
05/1/2025 20:18 | https://youtu.be/khV | bloomberg2 | |
05/1/2025 17:30 | https://youtu.be/jTC | bloomberg2 | |
05/1/2025 16:46 | https://www.creomedi | bloomberg2 | |
03/1/2025 17:20 | Cut them some slack, they are only up to Sep on the socials with the 12 days of Creo. | peterrr3 | |
03/1/2025 11:04 | C.mon Creo it's 2025 now!! Let's get moving | bloomberg2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions